

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**

**宜昌東陽光長江藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 01558)**

**POLL RESULTS OF  
THE ANNUAL GENERAL MEETING,  
2023 FIRST H SHAREHOLDERS CLASS MEETING AND  
2023 FIRST DOMESTIC SHAREHOLDERS CLASS MEETING  
HELD ON 2 JUNE 2023**

References are made to the notice of annual general meeting, the notice of 2023 first H Shareholders class meeting and the circular (the “**AGM Circular**”) of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) dated 24 April 2023, and the supplemental notice of annual general meeting and circular of the Company dated 17 May 2023 (the “**Supplemental Circular**”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the AGM Circular and the Supplemental Circular.

**POLL RESULTS OF AGM AND CLASS MEETINGS**

The AGM and the Class Meetings were convened and held at Conference Room, 4/F, Administration Building, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang’an County, Dongguan, Guangdong Province, the PRC on Friday, 2 June 2023. The AGM and the Class Meetings were convened lawfully and validly in accordance with the Company Law and other relevant laws and regulations of the PRC, the Listing Rules and the Articles of Association.

As at the date of the AGM and the Class Meetings, the total number of issued Shares of the Company was 879,967,700 Shares, including a total of 226,200,000 issued Domestic Shares and a total of 653,767,700 issued H Shares, all of which entitled the holders to attend and vote for or against or abstain from voting on the resolutions proposed at the AGM and/or the relevant Class Meetings.

- (a) Shareholders attending the AGM, either in person or by proxy, held an aggregate of 514,436,919 Shares with voting rights, representing approximately 58.460887% of the total number of the issued Shares with voting rights;

- (b) Shareholders attending the 2023 First H Shareholders Class Meeting, either in person or by proxy, held an aggregate of 279,129,119 H Shares with voting rights, representing approximately 42.695459% of the total number of the issued H Shares with voting rights; and
- (c) Shareholders attending the 2023 First Domestic Shareholders Class Meeting, either in person or by proxy, held an aggregate of 226,200,000 Domestic Shares with voting rights, representing 100.000000% of the total number of the issued Domestic Shares with voting rights.

No Shareholder was required to abstain from voting on resolutions numbered 1 to 7 proposed at the AGM and any of the resolutions proposed at the Class Meetings under the Listing Rules. Sunshine Lake Pharma is entitled to control the exercise of approximately 51.41% of voting rights of the Company and is therefore a controlling Shareholder and a connected person of the Company. Shenzhen HEC Industrial is the holding company of the Sunshine Lake Pharma. Therefore, as an associate of Sunshine Lake Pharma, Shenzhen HEC Industrial constitutes a connected person of the Company by virtue of being the holding company of the controlling Shareholder of the Company pursuant to Chapter 14A of the Listing Rules. Shenzhen HEC Industrial and its associates, such as Sunshine Lake Pharma and HEC (Hong Kong) Sales Co., Limited, were therefore deemed to have a material interest in the Continuing Connected Transaction Agreements entered into between the Company and Shenzhen HEC Industrial, and were required to abstain from voting on resolutions numbered 8 to 14 proposed at the AGM. Save as disclosed above, no Shareholder was required by the Listing Rules to abstain from voting on any of the resolutions proposed at the AGM.

There was no Share entitling the holder to attend the AGM and the Class Meetings and abstain from voting in favour of any of the proposed resolutions under Rule 13.40 of the Listing Rules. Save as disclosed above, no Shareholder has stated the intention in the AGM Circular or the Supplemental Circular to vote against or to abstain from voting on any of the proposed resolutions.

All the proposed resolutions were voted by way of poll. Computershare Hong Kong Investor Services Limited, the H Share registrar of the Company, acted as the scrutineer for vote-taking at the AGM and the Class Meetings. Two representatives from the Shareholders and one Supervisor of the Company also acted as the scrutineers for the vote-taking and vote-tabulation.

All Directors attended the AGM, the 2023 First H Shareholders Class Meeting and the 2023 First Domestic Shareholders Class Meeting.

## Poll Results of the AGM

The poll results of the AGM are as follows:

ORDINARY RESOLUTIONS		NUMBER OF VOTES AND PERCENTAGE OF TOTAL NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
1.	To review and approve the report of the Board of Directors of the Company for the year ended 31 December 2022.	492,243,519 (99.923227%)	0 (0.000000%)	378,200 (0.076773%)
2.	To review and approve the report of the Board of Supervisors of the Company for the year ended 31 December 2022.	514,058,719 (99.926483%)	0 (0.000000%)	378,200 (0.073517%)
3.	To review and approve the consolidated financial statements of the Company for the year ended 31 December 2022.	514,058,719 (99.926483%)	0 (0.000000%)	378,200 (0.073517%)
4.	To review and approve the 2022 annual report of the Company.	514,058,719 (99.926483%)	0 (0.000000%)	378,200 (0.073517%)
5.	To review and approve the re-appointment of KPMG as auditor of the Company for a term until the conclusion of the next annual general meeting of the Company, and authorize the Board of Directors to determine its remuneration.	514,361,519 (99.985343%)	75,400 (0.014657%)	0 (0.000000%)

As more than half of the votes from the Shareholders (including their proxies) attending the AGM were cast in favour of the resolutions numbered 1 to 5, these resolutions were duly passed as ordinary resolutions.

SPECIAL RESOLUTIONS		NUMBER OF VOTES AND PERCENTAGE OF TOTAL NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
6.	To consider and approve the general mandates to the Board to issue Shares.	500,497,352 (97.290325%)	13,864,167 (2.695018%)	75,400 (0.014657%)
7.	To consider and approve the general mandates to the Board to repurchase H Shares.	514,361,519 (99.985343%)	0 (0.000000%)	75,400 (0.014657%)

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the AGM were cast in favour of the resolutions numbered 6 and 7, these resolutions were duly passed as special resolutions.

ORDINARY RESOLUTIONS		NUMBER OF VOTES AND PERCENTAGE OF TOTAL NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
8.	THAT (a) the execution of the Energy Purchase Framework Agreement (as defined in the Supplemental Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Energy Purchase Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Supplemental Circular be and are hereby approved.	40,221,719 (100.000000%)	0 (0.000000%)	0 (0.000000%)
9.	THAT (a) the execution of the APIs Purchase Agreement (as defined in the Supplemental Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the APIs Purchase Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Supplemental Circular be and are hereby approved.	40,221,719 (100.000000%)	0 (0.000000%)	0 (0.000000%)
10.	THAT (a) the execution of the Packaging and Production Materials Purchase Framework Agreement (as defined in the Supplemental Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Packaging and Production Materials Purchase Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Supplemental Circular be and are hereby approved.	40,221,719 (100.000000%)	0 (0.000000%)	0 (0.000000%)
11.	THAT (a) the execution of the Equipment Purchase and Civil Construction Framework Agreement (as defined in the Supplemental Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Equipment Purchase and Civil Construction Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Supplemental Circular be and are hereby approved.	40,221,719 (100.000000%)	0 (0.000000%)	0 (0.000000%)

ORDINARY RESOLUTIONS		NUMBER OF VOTES AND PERCENTAGE OF TOTAL NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
12.	THAT (a) the execution of the Entrusted Processing Framework Agreement (as defined in the Supplemental Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Entrusted Processing Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Supplemental Circular be and are hereby approved.	40,221,719 (100.000000%)	0 (0.000000%)	0 (0.000000%)
13.	THAT (a) the execution of the Equipment Sales Framework Agreement (as defined in the Supplemental Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Equipment Sales Framework Agreement and the proposed annual cap for the year ending 31 December 2023 as set out in the Supplemental Circular be and are hereby approved.	40,221,719 (100.000000%)	0 (0.000000%)	0 (0.000000%)
14.	THAT (a) the execution of the Entrusted Production and Inspection Services Framework Agreement (as defined in the Supplemental Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Entrusted Production and Inspection Services Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Supplemental Circular be and are hereby approved.	40,221,719 (100.000000%)	0 (0.000000%)	0 (0.000000%)

As more than half of the votes from the Shareholders (including their proxies) attending the AGM were cast in favour of the resolutions numbered 8 to 14, these resolutions were duly passed as ordinary resolutions.

## Poll Result of the 2023 First H Shareholders Class Meeting

The poll result of the 2023 First H Shareholders Class Meeting is as follows:

SPECIAL RESOLUTION		NUMBER OF VOTES AND PERCENTAGE OF TOTAL NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the general mandates to the Board to repurchase H Shares.	279,047,719 (99.970838%)	6,000 (0.002149%)	75,400 (0.027013%)

As more than two-thirds of the votes from the H Shareholders (including their proxies) attending the 2022 First H Shareholders Class Meeting were cast in favour of the above resolution, this resolution was duly passed as a special resolution.

## Poll Result of the 2023 First Domestic Shareholders Class Meeting

The poll result of the 2023 First Domestic Shareholders Class Meeting is as follows:

SPECIAL RESOLUTION		NUMBER OF VOTES AND PERCENTAGE OF TOTAL NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the general mandates to the Board to repurchase H Shares.	226,200,000 (100.000000%)	0 (0.000000%)	0 (0.000000%)

As more than two-thirds of the votes from the Domestic Shareholders (including their proxies) attending the 2023 First Domestic Shareholders Class Meeting were cast in favour of the above resolution, this resolution was duly passed as a special resolution.

On behalf of the Board  
**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**  
**TANG Xinfa**  
*Chairman*

Hubei, the PRC

2 June 2023

*As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive Directors; Mr. TANG Xinfa as non-executive Director; and Mr. TANG Jianxin, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive Directors.*